Rosetta Genomics Reports First Quarter 2008 Financi... (chnology the test is being developed tod...)

Rosetta Genomics Reports First Quarter 2008 Financial Results

Date:5/21/2008

chnology, the test is being developed to distinguish among more than 20 possible tissues of origin, and it is expected to be submitted for regulatory approval in H2 2008.

- Additional diagnostic tests - We continued the expansion of our microRNA-based diagnostic pipeline with cancer-related indications and indications related to women's health.

- Identified microRNAs that are potential biomarkers for differential diagnosis of the following in lung cancer: primary vs. metastases, non-small cell lung cancer vs. small-cell lung cancer, neuroendocrine tumors vs. non-small cell lung cancer, lung cancer vs. thymoma, and carcinoid vs. other neuroendocrine tumors.

- Identified specific microRNAs that are markers to differentiate between primary liver and brain tumors and metastases to these organs.

- Women's health: Demonstrated correlation between microRNAs in serum and physiological conditions.

Collaborations and Licensing

- Initiated a collaboration with the Henry Ford Health System in Detroit, Michigan, to develop microRNA-based diagnostics and prognostics for brain cancer. Under the collaboration, the parties will conduct a genome-wide molecular analysis of human brain cancer tumors to identify unique microRNA biomarkers that have diagnostic and prognostic potential.

- Signed an agreement with University of California, Irvine School of Medicine, relating to the development and validation of diagnostic tests based on the company's microRNA technology. The tests are designed to differentiate squamous versus non-squamous lung cancer, differentiate mesothelioma from adenocarcinoma, and identify cancers of unknown primary (CUP) origin.

Intellectual Property

- The U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two of the company's patent applications on human (10/604,726) and viral (10/604,942) microRNAs. The first allowed patent application (10/604,726) is related to two clustered
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer

Post Your Comments:

Rosetta Genomics Reports First Quarter 2008 Financi...(chnology the test is being developed tod...)